4575.T
CanBas Co.,Ltd.
グロース · 医薬品 · 医薬品 · JP
JPY 766.00
+0.39%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | — | — | — | — | — |
| Cost and Expenses | — | — | — | — | — |
| Operating Income (EBIT) | (1.2B) | (1.1B) | (1.3B) | (965.0M) | (846.0M) |
| Non-Operating | |||||
| Interest Income | 3.5M | 1.4M | 32.0K | 21.0K | 17.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | (36.3M) | (47.1M) | 53.7M | (317.1M) | (7.9M) |
| Non-Operating Income (excl Interest) | 29.7M | 1.0K | 59.3M | 4.0M | 666.0K |
| EBT (Pre-Tax Income) | (1.2B) | (1.2B) | (1.2B) | (1.2B) | (854.3M) |
| Income Tax Expense | 1.3M | 1.3M | 1.3M | 1.3M | 1.3M |
| Bottom Line | |||||
| Net Income | (1.2B) | (1.2B) | (1.2B) | (1.2B) | (855.0M) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.2B) | (1.2B) | (1.2B) | (1.2B) | (855.0M) |
| Per Share | |||||
| Basic EPS | (¥65) | (¥61) | (¥68) | (¥83) | (¥88) |
| Diluted EPS | (¥65) | — | — | — | — |
| Revenue Per Share | — | — | — | — | — |
| Shares | |||||
| Basic Shares Outstanding | 19.7M | 18.9M | 17.8M | 15.0M | 9.7M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | — | — | — | — |
| D&A | — | — | — | — | — |
| EBIT | (1.2B) | (1.1B) | (1.3B) | (965.0M) | (846.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026